These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22171554)

  • 21. [Quality control of oral anticoagulant therapy in Primary Care in Madrid City, Spain: CHRONOS-TAO study].
    Alonso Roca R; Figueroa Guerrero CA; Mainar de Paz V; Arribas García MP; Sánchez Perruca L; Rodríguez Barrientos R; Casado López M; Pedraza Flechas AM
    Med Clin (Barc); 2015 Sep; 145(5):192-7. PubMed ID: 25433789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of pharmacist-managed oral anticoagulation therapy in older veterans.
    Poon IO; Lal L; Brown EN; Braun UK
    J Clin Pharm Ther; 2007 Feb; 32(1):21-9. PubMed ID: 17286786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery.
    Meijer K; Kim YK; Carter D; Schulman S
    Thromb Haemost; 2011 Feb; 105(2):232-8. PubMed ID: 21173999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction between warfarin and nafcillin: case report and review of the literature.
    Kim KY; Frey RJ; Epplen K; Foruhari F
    Pharmacotherapy; 2007 Oct; 27(10):1467-70. PubMed ID: 17896903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International Normalized Ratio (INR): an improved way to monitor oral anticoagulant therapy.
    Oertel LB
    Nurse Pract; 1995 Sep; 20(9):15-6, 21-2. PubMed ID: 7501312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of warfarin control in atrial fibrillation patients in South East Queensland, Australia.
    Bernaitis N; Badrick T; Davey AK; Anoopkumar-Dukie S
    Intern Med J; 2016 Aug; 46(8):925-31. PubMed ID: 27040159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.
    Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA;
    Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Audit of community-based anticoagulant monitoring in patients with thromboembolic disease: is frequent testing necessary?
    Young L; Ockelford P; Harper P
    Intern Med J; 2004 Nov; 34(11):639-41. PubMed ID: 15546458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of factors affecting time in therapeutic range control after warfarin administration.
    Kose E; Arai S; An T; Kikkawa A; Aoyama T; Matsumoto Y; Hayashi H
    Pharmazie; 2015 Jul; 70(7):494-8. PubMed ID: 26373212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of medication timing on anticoagulation stability in users of warfarin (the INRange RCT): study protocol for a randomized controlled trial.
    Heran BS; Allan GM; Green L; Korownyk C; Kolber M; Olivier N; Flesher M; Garrison S
    Trials; 2016 Aug; 17(1):391. PubMed ID: 27488365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction between gemfibrozil and warfarin: case report and review of the literature.
    Dixon DL; Williams VG
    Pharmacotherapy; 2009 Jun; 29(6):744-8. PubMed ID: 19476425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Home prothrombin time monitoring: a literature analysis.
    Yang DT; Robetorye RS; Rodgers GM
    Am J Hematol; 2004 Oct; 77(2):177-86. PubMed ID: 15389909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of factor II and factor X as therapeutic markers in patients under chronic warfarin therapy.
    Costa IM; Serralheiro AI; Rodrigues M; Alves G; Falcão AC
    Biomed Pharmacother; 2010 Feb; 64(2):130-2. PubMed ID: 20045627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreasing warfarin sensitivity during the first three months after heart valve surgery: implications for dosing.
    Meijer K; Kim YK; Schulman S
    Thromb Res; 2010 Mar; 125(3):224-9. PubMed ID: 19336266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated international normalized ratio from vitamin K supplement discontinuation.
    Miesner AR; Sullivan TS
    Ann Pharmacother; 2011 Jan; 45(1):e2. PubMed ID: 21205949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Warfarin related intracranial haemorrhage: a case-controlled study of anticoagulation monitoring prior to spontaneous subdural or intracerebral haemorrhage.
    Jeffree RL; Gordon DH; Sivasubramaniam R; Chapman A
    J Clin Neurosci; 2009 Jul; 16(7):882-5. PubMed ID: 19342242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of the switch from a branded to a generic warfarin sodium product: an observer-blinded, randomized, crossover study.
    Lee HL; Kan CD; Yang YJ
    Clin Ther; 2005 Mar; 27(3):309-19. PubMed ID: 15878384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of hospitalization on oral anticoagulation control: a population-based study.
    van Walraven C; Austin PC; Oake N; Wells P; Mamdani M; Forster AJ
    Thromb Res; 2007; 119(6):705-14. PubMed ID: 16844204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient factors that influence warfarin dose response.
    White PJ
    J Pharm Pract; 2010 Jun; 23(3):194-204. PubMed ID: 21507814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.